Highlights

  • Cleveland Clinic has commenced clinical use of CT:VQ™ under a commercial arrangement.
  • The site becomes the third major U.S. academic medical centre to deploy CT:VQ™.
  • The agreement includes a one-month introductory pricing period before standard commercial terms.

4DMedical Limited (ASX:4DX) has announced that Cleveland Clinic has entered into a commercial arrangement for the clinical use of its CT:VQ™ respiratory imaging technology. The agreement allows for an initial one-month introductory pricing period, designed to support integration into clinical workflows, after which full commercial terms will apply.

Cleveland Clinic is regarded as one of the most prominent healthcare institutions in the United States, with a strong focus on clinical care, research, and medical education. Its adoption of CT:VQ™ expands the technology’s footprint among large academic medical centres (AMCs) in the U.S. healthcare system.

Third Major Academic Medical Centre in Three Months
The Cleveland Clinic agreement represents the third deployment of CT:VQ™ at a leading U.S. academic medical centre since the product received FDA clearance. Previous clinical use arrangements were established at Stanford University and the University of Miami.

The three AMC deployments have been completed within approximately three months of regulatory clearance, highlighting early institutional uptake following approval. Academic medical centres often play a key role in evaluating and implementing new diagnostic technologies, particularly those intended for broader clinical adoption.

Commercial Structure and Introductory Pricing
Under the terms of the arrangement, Cleveland Clinic will access CT:VQ™ under an introductory pricing structure for one month. This period is intended to allow clinicians and operational teams to incorporate the technology into existing imaging and diagnostic pathways. Following this introductory phase, the agreement will transition to standard commercial pricing terms.

The structure mirrors previous commercial arrangements announced by the company at other U.S. academic institutions, applying a consistent approach to early-stage clinical adoption.

Growing Network of U.S. Reference Sites
With Cleveland Clinic joining Stanford University and the University of Miami, CT:VQ™ is now in clinical use across multiple high-profile U.S. academic institutions. These sites collectively form a network of reference users for the technology within the academic healthcare sector.

Academic medical centres typically influence diagnostic practices across affiliated hospitals, training programs, and research networks. As a result, early adoption at these institutions is often monitored by other healthcare providers assessing new imaging approaches.

Focus on Advanced Respiratory Imaging
CT:VQ™ is designed to provide functional lung imaging using computed tomography, offering an alternative approach to traditional nuclear-based ventilation-perfusion imaging. The Cleveland Clinic deployment supports ongoing clinical evaluation of the technology in real-world hospital settings.

Share Price Snapshot
4DX was trading  24.91% higher at AUD 3.610 per share as of 19 December 2025.